logo
  

Medicago, GSK Start Phase 2/3 Trials Of Adjuvanted COVID-19 Vaccine Candidate

Medicago said that it has decided to start phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. The COVID-19 vaccine candidate will contain GlaxoSmithKline plc.'s (GSK.L,GSK) pandemic adjuvant.

The move was based on the positive Phase 1 results and the approval of Canadian regulatory authorities.

Thomas Breuer, Chief Medical Officer GSK Vaccines said "...We are delighted with the very promising Phase 1 results of Medicago's COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant."

The Coronavirus-Like Particle COVID-19 vaccine candidate, CoVLP is composed of recombinant spike (S) glycoprotein expressed as virus-like particles or VLPs.

According to the company, the study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP (two doses of 3.75 µg CoVLP combined with GSK's pandemic adjuvant given 21 days apart) has an acceptable immunogenicity and safety profile in healthy adults 18-64 years of age and in elderly subjects aged 65 and over.

The Phase 2 trial will evaluate the safety and immunogenicity of the adjuvanted recombinant COVID-19 plant-derived vaccine candidate in subjects aged 18 and above.

Medicago noted that the phase 3 part of the study should start before the end of 2020. The phase 3 clinical trial will enroll over 30,000 volunteers worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT